Lyell Immunopharma Initiates Phase 3 Head-to-Head CAR T-Cell Trial

요약

“Lyell Immunopharma has initiated patient dosing in PiNACLE – H2H Phase 3 trial”
“Trial compares rondecabtagene autoleucel (ronde-cel) against lisocabtagene maraleucel and axicabtagene ciloleucel”
“This is the first randomized controlled CAR T-cell trial comparing different therapies”

Profit ▼ Debt low Cash good Valuation neutral Drawdown neutral Recent decline

라이엘 이뮤노파마, 3상 헤드-투-헤드 CAR T-세포 임상시험 시작
라이엘 이뮤노파마, PiNACLE – H2H 3상 임상시험 환자 투약 시작
론데셀을 리소셀 및 아시셀과 비교하는 시험
다양한 치료법을 비교하는 최초의 무작위 대조 CAR T-세포 시험

출처: GlobeNewswire
링크: https://www.globenewswire.com/news-release/2026/02/12/3237094/0/en/lyell-immunopharma-announces-initiation-of-patient-dosing-in-first-of-its-kind-phase-3-head-to-head-car-t-cell-clinical-trial-in-aggressive-large-b-cell-lymphoma.html

소셜 공유 미리보기(OG) 전용 페이지입니다.